Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06124937
Other study ID # IRCT20230110057098N1
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 7, 2023
Est. completion date December 30, 2024

Study information

Verified date November 2023
Source Rajaie Cardiovascular Medical and Research Center
Contact Hessam Kakavand, PharmD
Phone +982144605351
Email hessamkakavand@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication. The goal of present study is to investigate if periprocedural administration of 10 mg once daily empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2I), can reduce the incidence of post-operative atrial fibrillation and/or atrial flutter in patients with chronic coronary syndrome scheduled for isolated CABG. This trial will be conducted in two referral teaching cardiology hospitals in Tehran. 492 adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting 3 days before surgery until discharge.


Description:

Study aim: Evaluating the role of empagliflozin on the rate of postoperative atrial fibrillation in comparison with placebo Design: Two arms, parallel-group, phase 3, randomized, double-blind, placebo-controlled trial on 492 patients Settings and conduct: Recruitment site: Tehran Heart Center and Rajaie Cardiovascular Medical and Research Center For blinding, the drug or placebo will be given to the ward based on the patient's code in the randomization system For monitoring, the blood samples for creatinine, sodium, potassium, and fasting blood sugar along with clinical evaluations will be given on day 0 and daily thereafter (max= 30 days) in specific wards and will be compared at the end of any atrial fibrillation lasting longer than 30 seconds based on 24-hour 12-lead ECG monitoring will be accepted as atrial fibrillation After entering the study, the patients are placed in one of two groups, sample and control; in the sample group, they are treated with the usual treatment regimen plus empagliflozin at a dose of 10 mg during the hospitalization period. Patients in the control arm will receive a matching placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 492
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria - Adult patients (=18 years) who are candidates for isolated CABG - Patients who provided written informed consent and are willing to participate in the study Exclusion criteria - History of type ? or ? diabetes mellitus - History of ketoacidosis - History of atrial fibrillation or flutter - History of recurrent UTI - SGLT2I or any other oral hypoglycemic medications used due to other indications - Patients with acute kidney injury (45) - Severe hepatic disease (Child-Pugh score C) - Patients with Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73m2 - Patients who are candidates for emergent CABG - Patients with unstable hemodynamic state - Patients with positive urine culture, urinary symptoms (frequency, dysuria, hesitancy), and asymptomatic bacteriuria - Patients who are enrolled in other clinical trials - Patients with a history of drug-sensitive reactions to SGLT2I - Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Empagliflozin 10 MG
The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
Placebo
The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.

Locations

Country Name City State
Iran, Islamic Republic of Rajaie Cardiovascular Medical & Research Center Tehran
Iran, Islamic Republic of Tehran Heart Center Tehran

Sponsors (2)

Lead Sponsor Collaborator
Rajaie Cardiovascular Medical and Research Center Tehran Heart Center

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of POAF Incidence of new-onset postoperative atrial fibrillation (AF) and/or atrial flutter (AFL), defined as any adjudicated documented AF or AFL of at least 30 seconds duration and documented by Holter ECG monitoring during the admission time in the ICU (at least 72 hours and maximum 30 days). From CABG until discharge from the intensive care unit (at least 72 hours and maximum 30 days)
Secondary Composite Incidence of all arrhythmias leading to hemodynamic instability Defined as any adjudicated documented tachy- or bradyarrhythmia of at least 30 seconds duration and documented by rhythm strips or 12-lead ECG leading to hemodynamic instability during the admission time. Ventricular tachycardia (VT) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG.
Ventricular fibrillation (VF) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG
From CABG until discharge from the hospital (maximum 30 days).
Secondary Incidence of post-operative acute kidney injury Defined as the presence of either the increase in serum creatinine by = 0.3 mg/dl (= 26.5 µmol/l) within 48 hours; or an increase in serum creatinine to = 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume < 0.5 ml/kg/h for 6 hours based on the KDIGO definition of AKI From CABG until 7th post-operation day.
Secondary Need for vasopressor/inotrope Defined as cumulative vasopressor index and the amount of average daily inotrope dose during the admission time in the ICU From CABG until discharge from the intensive care unit (maximum 30 days).
Secondary Duration of hospitalization Defined as number of days a patient stay at the hospital From CABG until discharge from the hospital.
Secondary All-cause mortality Defined as adjudicated 30-day mortality, including cause-specific mortality: cardiac arrhythmic, cardiac non-arrhythmic, and non-cardiovascular. From CABG until 30th post-operation day.
Secondary Incidence of life-threatening infections Defined as any adjudicated laboratory and clinically confirmed systemic infection that necessitate the administration of parenteral broad spectrum antibiotics From CABG until discharge (maximum 30 days).
Secondary Incidence of genitourinary tract infections Defined as any adjudicated laboratory and clinically confirmed genitourinary tract infection including cystitis, pyelonephritis, prostatitis, urethritis, and vaginitis From CABG until discharge from the hospital (maximum 30 days).
Secondary Incidence of hypoglycemia Defined as serum blood sugar = 70 mg/dL (= 3.9 mmol/L) From CABG until discharge from the hospital (maximum 30 days).
Secondary Incidence of ketoacidosis Defined as blood pH = 7.3, serum bicarbonate less than 15 mEq/l, and presence of ketonemia or ketonuria From CABG until discharge from the hospital (maximum 30 days).
Secondary Incidence of clinically-diagnosed ischemic stroke Defined as the sudden loss of blood circulation to an area of the brain that has been confirmed with appropriate diagnostic imaging (Brain CT/MRI) From CABG until 30th post-operation day.
Secondary Composite incidence of arterial and venous thrombosis Defined as adjudicated arterial thrombosis (including Type I MI and peripheral arterial thrombosis) and venous thrombosis (including DVT and PE) confirmed with appropriate diagnostic tools From CABG until 30th post-operation day.
Secondary Need for renal replacement therapy defined as treatment with any forms of dialysis (hemodialysis, hemodiafiltration, and peritoneal dialysis), hemofiltration, and renal transplantation From CABG until discharge from the intensive care unit (maximum 30 days).
See also
  Status Clinical Trial Phase
Completed NCT01956708 - Transfer of Cardioprotection During RIPC N/A
Completed NCT01928745 - Experimental Determination of Atot en Ka in the Critically Ill N/A
Active, not recruiting NCT00966654 - Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery Phase 2
Completed NCT01282671 - Effects of Deep Breathing Exercises Two Months After Cardiac Surgery Phase 2
Completed NCT00524901 - Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia Phase 2
Completed NCT03050489 - Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Completed NCT00269243 - Management With Accupril Post Bypass Graft Phase 4
Recruiting NCT03139929 - Measurement of MSFP and Stressed Volume With CardioQ+®
Active, not recruiting NCT03424941 - The TransCatheter Valve and Vessels Trial N/A
Completed NCT06317363 - Effects of Acapella VS CHEST Physiotherapy in Post-Operative CABG Patients N/A
Completed NCT05023083 - Cross Cultural Adaptation of Functional Status Questionnaire in Urdu Language in CABG Patients
Completed NCT03800264 - Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Phase 4
Completed NCT05285865 - Scapular Mobilization on Inspiratory Capacity of Post-CABG Patients N/A
Not yet recruiting NCT06173609 - Long LIMA Patch on Left Anterior Descending Coronary Artery in CABG
Not yet recruiting NCT06238011 - Dexmedetomidine vs Control on Attenuation Hemodynamic Response to Noxious Stimuli in CABG Surgical Patients N/A
Active, not recruiting NCT06127147 - High-intensity Inspiratory Muscle Training as a Pre-cardiac Rehabilitation in Heart Disease N/A
Recruiting NCT06029556 - Effects of Early Mobility Protocols in Cardiac ICU N/A
Enrolling by invitation NCT01205620 - IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery Phase 2